±èÀ±ÁØ ¸íÀÇ

°£ºÎÀü ȯÀÚ, °£ ÀÌ½Ä ÇÊ¿ä ¿©ºÎ ¿¹Ãø ¸ðµ¨ °³¹ß

±èÀ±ÁØ ¸íÀÇ

  • ¼Ò ¼Ó
    ¼­¿ï´ëº´¿ø ¼ÒÈ­±â³»°ú
  • Àü¹®ºÐ¾ß
    °£¾Ï, ¸¸¼ºBÇü°£¿°, ¸¸¼ºCÇü°£¿°, °£°æº¯À» µ¿¹ÝÇÑ ½ÉÇÑ Áö¹æ°£

ÁÖ¿ä Áø·á ºÐ¾ß´Â ¸¸¼º°£¿°, °£¼¶À¯È­, °£°æº¯Áõ, °£¼¼Æ÷¾ÏÁ¾, ±Þ¼º°£ºÎÀü, °£ÀÌ½Ä µî °£ÁúȯÀ¸·Î °£¾Ï ȯÀÚ¸¦ À§ÇÑ Àü¹® Ŭ¸®´ÐÀ» ¿î¿µÇϰí ÀÖ´Ù.
°£¾ÏÀÇ º´Å»ý¸®ÇÐ, ¸¸¼ºBÇü°£¿°ÀÇ À¯ÀüÀû ¿äÀο¡ ´ëÇÑ ¿¬±¸¿¡ ÀÖ¾î ¼¼°èÀû ¼öÁØÀ̸ç, Áö¹æ°£, °£¾Ï¿¡ ´ëÇÑ ½Å¾à Ä¡·á¿¡ ÁýÁßÇÑ´Ù. Ȱ¹ßÇÑ Àӻ󿬱¸´Â ¹°·Ð ¿©·¯±â°ü¿¡¼­ ÀÌ·ïÁö´Â ¸é¿ªÄ¡·á °ü·Ã ¿¬±¸µµ ÁÖµµÇϰí ÀÖ´Ù. 2018³â 10¿ù¿¡´Â AÇü °£¿°¿¡ ÀÇÇÑ ±Þ¼º °£ºÎÀü ȯÀÚ¿¡°Ô Á¶±â °£À̽ÄÀÌ ÇÊ¿äÇÑÁö, »ç¸Á À§ÇèÀº ¾î´À Á¤µµÀÎÁö ¿¹ÃøÇÏ´Â ¿¹ÈÄÆò°¡ ¸ðµ¨À» °³¹ßÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ³»°úÇÐ ÀÇÇйڻç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ³»°úÇÐ ÀÇÇм®»ç
  • ¼­¿ï´ëÇб³ Àǰú´ëÇÐ ÀÇÇаú

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) ¼­¿ï´ëÇб³º´¿ø ³»°ú ±³¼ö

ÇÐȸȰµ¿

Academic activities
  • 2015 ~ ÇöÀç´ëÇѰ£ÇÐȸ °£ÇàÀÌ»ç
  • 2015 ~ ÇöÀçEditor-in-chief, Clinical and Molecular Hepatology
  • 2012 ~ ÇöÀç´ëÇѹæ»ç¼±»öÀü¼ú¿¬±¸È¸ ÇмúÀ§¿øÀå
  • 2002 ~ ÇöÀç´ëÇѳ»½Ã°æÇÐȸ Á¤È¸¿ø
  • 2002 ~ ÇöÀç´ëÇѹæ»ç¼±»öÀü¼ú¿¬±¸È¸ ÇмúÀ§¿øÀå
  • 2000 ~ ÇöÀç´ëÇѼÒÈ­±âÇÐȸ Æò»ýȸ¿ø
  • 2002 ~ ÇöÀç´ëÇѰ£ÇÐȸ Á¤È¸¿ø
  • 2000 ~ ÇöÀç´ëÇѼÒÈ­±âÇÐȸ Æò»ýȸ¿ø
  • 1997 ~ ÇöÀç´ëÇѳ»°úÇÐȸ Á¤È¸¿ø
  • 1992 ~ ÇöÀç´ëÇÑÀÇ»çÇùȸÁ¤È¸¿ø
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 4°Ç
Á¦ ¸ñ ±èÁ¤·æ ¼ÒÈ­±â°è Áúȯ Á¦3ÆÇ
ÃâÆÇ»ç ÀÏÁ¶°¢ ¹ßÇàÀÏ 2011.01
Á¦ ¸ñ Ãé´ãµµ¿Ü°úÇÐ
ÃâÆÇ»ç ¹ßÇàÀÏ 2011.12
Á¦ ¸ñ °èÅ뺰 ¾à¹° À¯ÇعÝÀÀ
ÃâÆÇ»ç ¹ßÇàÀÏ 2010
Á¦ ¸ñ ¾à¹°¿ªÇÐÀ§Çذü¸®
ÃâÆÇ»ç ¹ßÇàÀÏ 2009
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 7°Ç
Á¦ ¸ñ Research Profiles
¹ßÇ¥³âµµ ¹ßÇ¥Áö Pure (Elsevier)
Á¦ ¸ñ Direct-acting antivirals improve treatment outcomes in patients with hepatitis c virus-related hepatocellular carcinoma treated with transarterial chemoembolization: a nationwide, multi-center, retrospective cohort study.
¹ßÇ¥³âµµ 2021-7 ¹ßÇ¥Áö DIGESTIVE DISEASES AND SCIENCES
Á¦ ¸ñ Patterns and outcomes in hepatocellular carcinoma patients with portal vein invasion: a multicenter prospective cohort study.
¹ßÇ¥³âµµ 2021-1 ¹ßÇ¥Áö DIGESTIVE DISEASES AND SCIENCES
Á¦ ¸ñ Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of hbsag seroreversion after antiviral-induced hbsag seroclearance: a nationwide multicentre study.
¹ßÇ¥³âµµ 2020-2 ¹ßÇ¥Áö GUT
Á¦ ¸ñ A non-synonymous variant rs12614 of complement factor b associated with risk of chronic hepatitis b in a korean population.
¹ßÇ¥³âµµ 2020-2 ¹ßÇ¥Áö BMC MEDICAL GENETICS
Á¦ ¸ñ Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: a randomized prospective comparative study.
¹ßÇ¥³âµµ 2020-9 ¹ßÇ¥Áö PLOS ONE
Á¦ ¸ñ Glecaprevir-pibrentasvir to treat chronic hepatitis c virus infection in asia: two multicentre, phase 3 studies-a randomised, double-blind study (voyage-1) and an open-label, single-arm study (voyage-2).
¹ßÇ¥³âµµ 2020-9 ¹ßÇ¥Áö LANCET GASTROENTEROLOGY & HEPATOLO

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

¼­¿ï´ëº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-5700
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

¼­¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼­ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ­¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.

¼­¿ï´ëº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä